Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy

Lupus

Volumn 24, Issue 10, 2015, Pages 1029-1036

  Chen, M H ^a,b   Tsai, C Y ^a,b   Chou, C T ^a,b   Lin, H Y ^a,b   Huang, D F ^a,b   Huang, Y H ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

HCV reactivation; immunosuppression; interferon; late relapse; Systemic lupus erythematosus; virological response

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HEPATITIS B SURFACE ANTIGEN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS ANTIBODY; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; GLUCOCORTICOID;

ADULT; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE DISEASE; CORTICOSTEROID THERAPY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KAPLAN MEIER METHOD; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MORTALITY; PHYSIOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; VIROLOGY; VIRUS ACTIVATION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84938795600     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315571465     Document Type: Article

References (34)

1. Santini GF, Crovatto M, Giannini F, Bortolin MT, Mazzaro C, Invernizzi F,. Hepatitis C virus and immunoglobulin gene rearrangements: an early step in lymphomagenesis? Acta Haematol 1998; 100: 117-122.
2. Sung JL,. Prevention of hepatitis B and C virus infection for prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S370-S376.
3. Chuang WL, Chang WY, Lu SN,. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer 1992; 69: 2052-2054.
4. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y,. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-337.
5. Alter MJ,. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-S9.
6. Mahale P, Kontoyiannis DP, Chemaly RF,. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012; 57: 1177-1185.
7. Hoofnagle JH,. Reactivation of hepatitis B. Hepatology 2009; 49: S156-S165.
8. Huang YH, Hsiao LT, Hong YC,. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772.
9. Torres HA, Davila M,. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9: 156-166.
10. Faggioli P, De Paschale M, Tocci A,. Acute hepatic toxicity during cyclic chemotherapy in non-Hodgkin's lymphoma. Haematologica 1997; 82: 38-42.
11. Kawatani T, Suou T, Tajima F,. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67: 45-50.
12. Nosotti L, D'Andrea M, Pitidis A,. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy. Scand J Infect Dis 2012; 44: 70-73.
13. Bagavant H, Deshmukh US, Gaskin F, Fu SM,. Lupus glomerulonephritis revisited 2004: autoimmunity and end-organ damage. Scand J Immunol 2004; 60: 52-63.
14. Bertsias G, Ioannidis JP, Boletis J,. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.
15. Magy N, Cribier B, Schmitt C,. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999; 21: 253-261.
16. Humar A, Crotteau S, Gruessner A,. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes. Clin Transplant 2007; 21: 526-531.
17. Ciesek S, Wedemeyer H,. Immunosuppression, liver injury and post-transplant HCV recurrence. J Viral Hepat 2012; 19: 1-8.
18. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
21. Vento S, Cainelli F, Mirandola F,. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347: 92-93.
22. Arcaini L, Merli M, Passamonti F,. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol 2010; 85: 46-50.
23. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG,. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196-199.
24. Yu ML, Dai CY, Huang JF,. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-559.
25. Yu ML, Dai CY, Huang JF,. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893.
26. Maylin S, Martinot-Peignoux M, Moucari R,. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-829.
27. Swain MG, Lai MY, Shiffman ML,. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601.
28. Giannini EG, Basso M, Savarino V, Picciotto A,. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31: 502-508.
29. Formann E, Steindl-Munda P, Hofer H,. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based antiviral therapy. Aliment Pharmacol Ther 2006; 23: 507-511.
30. Veldt BJ, Saracco G, Boyer N,. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504-1508.
31. Colson P, Bregigeon S, Tourres C, Solas C, Poizot-Martin I, Tamalet C,. Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient. J Clin Virol 2013; 58: 309-314.
32. Hara K, Rivera MM, Koh C,. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis 2014; 209: 38-45.
33. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
34. Papatheodoridis GV1, Manolakopoulos S, Liaw YF, Lok A,. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012; 57: 196-202.